Merck & Co., Inc. (MRK) Stake Decreased by Bridgeworth LLC

Bridgeworth LLC cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 14.9% in the 2nd quarter, HoldingsChannel reports. The fund owned 7,457 shares of the company’s stock after selling 1,310 shares during the period. Bridgeworth LLC’s holdings in Merck & Co., Inc. were worth $452,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Cobblestone Capital Advisors LLC NY grew its stake in shares of Merck & Co., Inc. by 0.4% during the second quarter. Cobblestone Capital Advisors LLC NY now owns 187,080 shares of the company’s stock valued at $11,356,000 after acquiring an additional 774 shares in the last quarter. Associated Banc Corp grew its stake in shares of Merck & Co., Inc. by 0.3% during the second quarter. Associated Banc Corp now owns 251,933 shares of the company’s stock valued at $15,293,000 after acquiring an additional 776 shares in the last quarter. Twin Capital Management Inc. grew its stake in shares of Merck & Co., Inc. by 0.3% during the second quarter. Twin Capital Management Inc. now owns 269,930 shares of the company’s stock valued at $16,385,000 after acquiring an additional 780 shares in the last quarter. Checchi Capital Advisers LLC grew its stake in shares of Merck & Co., Inc. by 3.0% during the second quarter. Checchi Capital Advisers LLC now owns 26,914 shares of the company’s stock valued at $1,634,000 after acquiring an additional 792 shares in the last quarter. Finally, Nicollet Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 2.2% during the second quarter. Nicollet Investment Management Inc. now owns 36,898 shares of the company’s stock worth $2,240,000 after purchasing an additional 805 shares during the last quarter. Institutional investors own 72.31% of the company’s stock.

Shares of NYSE MRK opened at $72.35 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a 52-week low of $52.83 and a 52-week high of $72.89. The stock has a market capitalization of $193.64 billion, a price-to-earnings ratio of 18.18, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 27th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.03. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. The firm had revenue of $10.47 billion for the quarter, compared to analysts’ expectations of $10.28 billion. During the same quarter last year, the company posted $1.01 earnings per share. Merck & Co., Inc.’s revenue was up 5.4% on a year-over-year basis. As a group, analysts anticipate that Merck & Co., Inc. will post 4.28 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, October 5th. Shareholders of record on Monday, September 17th were issued a $0.48 dividend. The ex-dividend date was Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a yield of 2.65%. Merck & Co., Inc.’s dividend payout ratio is currently 48.24%.

In other Merck & Co., Inc. news, major shareholder Merck & Co., Inc. bought 666,666 shares of the business’s stock in a transaction on Monday, October 1st. The shares were purchased at an average price of $15.00 per share, with a total value of $9,999,990.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Kenneth C. Frazier sold 279,850 shares of the firm’s stock in a transaction dated Tuesday, October 2nd. The stock was sold at an average price of $72.07, for a total transaction of $20,168,789.50. Following the completion of the transaction, the chairman now directly owns 971,800 shares in the company, valued at approximately $70,037,626. The disclosure for this sale can be found here. Insiders sold 929,360 shares of company stock worth $64,370,599 in the last three months. 0.32% of the stock is currently owned by corporate insiders.

Several equities analysts have recently commented on the stock. ValuEngine raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Tuesday. Citigroup set a $79.00 price target on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday. Barclays increased their price target on shares of Merck & Co., Inc. from $75.00 to $78.00 and gave the stock an “overweight” rating in a research report on Friday, October 12th. Finally, Credit Suisse Group increased their price target on shares of Merck & Co., Inc. from $71.00 to $81.00 and gave the stock an “outperform” rating in a research report on Thursday, October 11th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Merck & Co., Inc. currently has an average rating of “Buy” and a consensus price target of $70.24.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Read More: Stock Symbols and CUSIP Explained

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply